Growth Factors of the Future

References

• Eschbach J. W., et al. Correction of the anemia of end-stage renal disease with recombinant human ery-thropoietin: results of a combined phase I and II clinical trials. N. Engl. J. Med. 1987; 316: 73
   PubMed Web of Science ®Google Scholar
• Watson A. J., et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human ery-thropoietin. Am. J. Med. 1990; 89: 432
   PubMed Web of Science ®Google Scholar
• Brandt S. J., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hemato-poietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 1988; 318: 869
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Engl. J. Med. 1991; 324: 1773–1991
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., et al. The use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure following bone marrow transplantation. Blood 1990; 76: 245
   PubMed Web of Science ®Google Scholar
• Crawford J., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N. Engl. J. Med. 1991; 325: 164
   PubMed Web of Science ®Google Scholar
• Quesada J. R., et al. Treatment of hairy cell Leukemia with recombinant α-Interferon. Blood 1986; 68: 493
   PubMed Web of Science ®Google Scholar
• Krown. NEJM. 308–1071
   Google Scholar
• Weiss G. R., et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J. Clinical Oncology 1992; 10: 275
   PubMed Web of Science ®Google Scholar
• Singer J. W., Nemunaitis J. Recombinant growth factors in bone marrow transplantation. In:. Bone Marrow Transplantation, S. J. Forman, E. D. Thomas, K. G. Blume, (in press)
   Google Scholar
• Broxmeyer H. E., Williams D. E., Hangoc G., et al. Synergistic myelopoietic actions in vivo after administration to mice of combinations of purified natural murine colony-stimulatory 1, recombinant murine interleukin-3, and recombinant murine granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 1987; 84: 3871
   PubMed Web of Science ®Google Scholar
• Donahue R. E., et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988; 241: 1820
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., . Hematopoietic growth factors: Clinical applications. Current Therapy in Oncology, J. E Niederhu-ber, et al, 1992; 1–-8
   Google Scholar
• Roilides E., et al. Granulocyte colony-stimulating factor enhances the phagocytic and batcericidal activity of normal and defective human neutrophils. J of Infectious Dis 1991; 163: 579
   PubMed Web of Science ®Google Scholar
• DeVries E. G., et al. A double-blind, placebo controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res. 1991; 51: 116
   PubMed Web of Science ®Google Scholar
• Edmonson J. H., et al. Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: Apparent dose and schedule dependency. J Natl Cancer Inst 1989; 81: 1510
   PubMed Web of Science ®Google Scholar
• Estey E. H., et al. Treatment of poor prognosis, newly diagnosed acute mild Leukemia with Ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75: 1766
   PubMed Web of Science ®Google Scholar
• Bruno E., et al. Interacting cytokines regulate in vitro human megakaryocytopoiesis. Blood 1989; 73: 671
   PubMed Web of Science ®Google Scholar
• Lu L., et al. Effect of recombinant and purified human hematopoietic growth factors on in vitro colony formation by enriched populations of human megakaryocyte progenitor cells. Br J Haematol. 1988; 70: 149
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987; 317: 1545
   PubMed Web of Science ®Google Scholar
• Greenberg P. L., et al. The use of hematopoietic growth factors in the treatment of myelodysplastic syndromes. Cancer Surveys 1990; 9: 199
   PubMedGoogle Scholar
• Smith D. H. Use of hematopoietic growth factors for treatment of aplastic anemia. Am J Pediatr Hematol Oncology 1990; 12: 425
   PubMedGoogle Scholar
• Groopman J. E., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med. 1987; 317: 593
   PubMed Web of Science ®Google Scholar
• Grossberg H. S., et al. GM-CSF with gancyclovir for the treatment of CVM retinitis in AIDS. N Engl J Med. 1989; 320: 1560
   PubMed Web of Science ®Google Scholar
• Pluda J. M., et al. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent in an alternating regimen with azidothymidine in leukpenic patients with severe human immunodeficiency virus infection. Blood 1990; 76: 463
   PubMed Web of Science ®Google Scholar
• Miller C. B., et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990; 322: 1689
   PubMed Web of Science ®Google Scholar
• Pincus T., et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89: 161
   PubMed Web of Science ®Google Scholar
• Goodnough L. T., et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med. 1989; 321: 1163
   PubMed Web of Science ®Google Scholar
• Evans R. W., et al. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263: 825
   PubMed Web of Science ®Google Scholar
• Foon K. A., et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med. 1984; 311: 1148
   PubMed Web of Science ®Google Scholar
• Elias L., et al. A trial of recombinant α2 interferon in the myelodysplastic syndromes: I. clinical results. Leukemia 1987; Vol 1(No. 2)105–-110, (February)
   Web of Science ®Google Scholar
• Foon K. A., et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 1985; 78: 216
   PubMed Web of Science ®Google Scholar
• Gutterman J. U., et al. Leukocyte interferon-induced tumor regression in human metastatic breast Cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1990; 93: 399
   Google Scholar
• Metcalf D. The consequences of excess levels of haemopoietic growth factors. B J of Haematology 1990; 75: 1
   PubMed Web of Science ®Google Scholar
• Shimoda K., et al. Granulocyte colony-stimulating factor in cerebrospinal fluid from patients with meningitis. Blood 1991; 11: 2214
   Google Scholar
• Gilbert H. S., et al. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: Association with myeloid metaplasia and peripheral bone marrow extension. Blood 1989; 74: 1231
   PubMed Web of Science ®Google Scholar
• Wagner D. K., et al. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lympho-mas: Correlation with survival. J of Clin Oncol 1987; 5: 1262
   PubMed Web of Science ®Google Scholar
• Raines M. A., et al. Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor. Proc Natl Acad Sci USA 1991; 88: 8203
   PubMed Web of Science ®Google Scholar
• Cairo M. S., et al. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: Endogenous G-CSF production correlates with myeloid engraftment. Blood 1992; 79: 1869
   PubMed Web of Science ®Google Scholar
• Herrmann F., et al. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. J of Clin Oncol. 1992; 10: 631
   PubMed Web of Science ®Google Scholar
• Lopez A. F., et al. Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci USA 1987; 84: 2761
   PubMed Web of Science ®Google Scholar
• Ishibashi T., Burstein S. A. Interleukin-3 promotes the differentiation of isolated single megakaryocytes. Blood 1986; 67: 1512
   PubMed Web of Science ®Google Scholar
• Gillio A. P., et al. Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclopho-sphamide treatment of cynomolgus primates. J Clin Invest 1990; 85: 1560
   PubMed Web of Science ®Google Scholar
• Oster W., Schultz G. Int J Cell Cloning 1991; 3: 5, Interleukin-: Biological and clinical effects., 9
   Google Scholar
• Donahue R. E., et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988; 241: 1820
   PubMed Web of Science ®Google Scholar
• Hoelzer D., et al. Interleukin 3 alone and in combination with GM-CSF in the treatment of patients with neoplastic disease. Seminars in Hematol. 1991; 28: 17024
   Google Scholar
• Williams D. E., et al. Hybrid cytokines as hematopoietic growth factors. Int J of Cell Cloning 1991; 9: 542
   PubMedGoogle Scholar
• Ralph P., et al. Biological properties and molecular biology of the human macrophage growth factor, CSF-1. Immunobiol 1986; 172(194)
   PubMedGoogle Scholar
• Karbassi A., et al. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: Evidence for augmented expression of mannose receptors. J. Immunol. 1987; 139: 417
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Singer J. W. Macrophage colony stimulating factor (M-CSF): Biology and clinical applications. High dose cancer therapy: Pharmacology, hematopoietics and stem cells, J. O. Armitage, K. H. Antman, 1992; 344–-361
   Google Scholar
• Nemunaitis J., et al. Phase I trial of recombinant human macrophage colony stimulating factor (rhM-CSF) in patients with invasive fungal infections. Blood 1991; 78: 907
   PubMed Web of Science ®Google Scholar
• Dinarello C., et al. Multiple biological activities of human recombinant interleukin-1. J Clin Invest 1986; 77: 1734
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., et al. Response of simian virus 40 (SV40) transformed, cultured human stromal cells to hematopoietic growth factors. J Clin Invest. 1989; 83: 593
   PubMed Web of Science ®Google Scholar
• Rennick D., et al. Control of hemopoiesis by a bone marrow stromal cell clone: Lipopolysaccharide and interleukin-1-inducible production of colony-stimulating factors. Blood 1987; 69: 682
   PubMed Web of Science ®Google Scholar
• Stanley E. R., et al. Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1. Cell 1986; 45: 667
   PubMed Web of Science ®Google Scholar
• Neta R., et al. Interleukin-1 is a radioprotector. J Immunol. 1986; 136: 2483
   PubMed Web of Science ®Google Scholar
• Moore M. A. S., et al. Hematologic effects of interleukin-tb˜, granulocyte colony-stimulating factor, and granulocyte-macrophage stimulating factor in tumor-bearing mice treated with fluorouracil. J Natl Cancer Inst 1990; 82: 1031
   PubMed Web of Science ®Google Scholar
• Masuda A., et al. Induction of mitochondrial manganese superoxide dismutase by interleukin-1. FASEB 1988; 2: 3087
   PubMed Web of Science ®Google Scholar
• Starnes H. F. Biological effects and possible clinical applications of interleukin-1. Semin Hematol. 1991; 28: 34
   PubMed Web of Science ®Google Scholar
• Gillis S. J Clin Immunol 1983; 2: 1, Interleukin: Biology and biochemistry., 3
   Web of Science ®Google Scholar
• Henney C. S., et al. Interleukin 2 augments natural killer cell activity. Nature 1981; 91: 335
   Web of Science ®Google Scholar
• Rosenberg S. A., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. NEJM 1987; 316: 889
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Duncombe A. S., Reittie J. E., Bello-Fernandez C., Gottleib D. J., Prentice H. G., Mehta A. B., Hoflbrand A. V., Brenner M. K. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Brit. J Haemal. 1991; 77: 237–244
   PubMed Web of Science ®Google Scholar
• Nishimura T., Ohta S., Sato N., Togashi Y., Goto M., Hashimoto Y. Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin-2 in mice. Int J Cancer 1987; 40: 255–261
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Cooper S., Lu L., Hangoc G., Anderson D., Cosman D., Lyman S. D., Williams D. E. Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood 1991; 77: 2142–2149
   PubMed Web of Science ®Google Scholar
• Zsebo K. M., Wypych J., McNiece I. K., Lu H. S., Smith K. A., Karkare S. B., Sachdev R. K., Yuschenkoff V. N., Birkett N. C., Williams L. R., Satyagal V. N., Tung W., Bosselman R. A., Mendiaz E. A., Langley K. E. Identification, purification, and biological characterization of hematopoietic stem cell factor from Buffalo rat liver-conditioned medium. Cell 1990; 63: 195–201, ;
   PubMed Web of Science ®Google Scholar
• Nemunaitis J. A rush on “stem cell factor”: Is it or isn't it?. Exp Hematol. 1991; 19: 997
   PubMed Web of Science ®Google Scholar
• Van Damme J., Cayphas S., Van Snick J., Conings R., Put W., Lenaerts J. P., Simpson R. J., Billiau A. Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). Eur J Biochem. 1987; 168: 543–550
   PubMedGoogle Scholar
• Quesenberry P. J., McGrath H. E., Williams M. E., Robinson B. E., Deacon D. H., Clark S., Urdal D., McNiece I. K. Multifactor stimulation of megakaryocytopoiesis: Effects of interleukin 6. Exp Hematol. 1991; 19: 35–41
   PubMed Web of Science ®Google Scholar
• Mayer P., Geissler K., Valent P., Ceska M., Bettelheim P., Liehl E. Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp Hematol. 1991; 19: 688–696
   PubMed Web of Science ®Google Scholar
• Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584–588
   PubMed Web of Science ®Google Scholar
• Van Der Poll T., Büller H. R., Cate H. T., Wortel C. G., Bauer K. A., van Deventer S. J. H., Hack C. E., Sauerwein H. P., Rosenberg R. D., Ten Cate J. W. Activation of coagulation after administration of tumor necrosis factor to normal subjects. NEJM 1990; 322: 1622–1627
   PubMed Web of Science ®Google Scholar
• Philip R., Epstein L. B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, τ-interferon and interleukin-1. Nature 1986; 323: 86–89
   PubMed Web of Science ®Google Scholar
• Wisniewski D., Strife A., Atzpodien J., Clarkson B. D. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia. Cancer Res. 1987; 47: 4788–4794
   PubMed Web of Science ®Google Scholar
• Bianco J., Appelbaum F. R., Nemunaitis J., Almgren J., Andrews F., Kettner P., Shields D., Singer J. W. Phase I-II trial of pentoxifylline for the prevention of transplant related toxicities following bone marrow transplantation. Blood 1991; 78: 1205–1211
   PubMed Web of Science ®Google Scholar
• Tepper R. I., Pattengale P. K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Namen A. E., Lupton S., Hjerrild K., Wignall J., Mochizuki D. Y., Schmierer A., Mosley B., March C. J., Urdal D., Gillis S., Cosman D., Goodwin R. G. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988; 333: 571–573
   PubMed Web of Science ®Google Scholar
• Limaye A. P., Abrams J. S., Silver J. E., Ottesen E. A., Nutman T. B. Regulation of parasite-induced eosinophilia: Selectiviely increased interleukin-5 production in helminth-infected patients. J. Exp Med. 1990; 172: 399–402
   PubMed Web of Science ®Google Scholar
• Conti P., Reale M., Barbacane R. C., Bongrazio M., Panara M. R., Fiore S., Dempsey R., Borish L. Leukocyte inhibitory factor activates human neutrophils and macrophages to release leukotriene B4 and thromboxanes. Cytokine 1990; 2: 142–148
   PubMedGoogle Scholar
• Baggiolini M., Walz A., Kunkel S. Neutrophil activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 1989; 840: 1045–1049
   Web of Science ®Google Scholar